Eric Lefkofsy’s Tempus technology firm will be collaborating with the Mayo Clinic which is considered as a prominent health-care facility.
Tempus is based in Chicago and makes use of analytics to help doctors in customizing their treatment for cancer patients. Tempus has joined forces with a number of hospitals and medical centers all around the world to expand its data. All this is an effort towards curing cancer.
Tempus will be providing molecular sequencing along with analysis for over 1,000 Mayo Clinic patients who will be participating in two of their research projects. In website, these are related to immunotherapy in bladder cancer, lung cancer, melanoma, breast cancer, and lymphoma besides endocrine therapy in case of breast cancer in advanced stages.
The goal of Eric Lefkofsky here is to improve the quality of life of patients by limiting their exposure to ineffective drugs along with unnecessary toxicity. Basically, the aim here is to improve their survival rates.
Eric Lefkofsky is the co-founder and CEO of Tempus. He says that he started this business when he believed there is a big problem that he had identified and now he wished to spend time in fixing it.
Eric Lefkofsky is well aware that technology has made a lot of advances over the last two decades. He is concerned that it has not yet permeated through the healthcare system completely. The operating system and analytical technology of Tempus is being taken to Mayo in order to benefit physicians as well as patients in their fight against cancer.
There are a number of medical institutions that are working with Tempus. These include the Lurie Comprehensive Cancer Center of Northwestern University, Rush University Medical Center, in addition to a clinical trial group at the University of Chicago along with the Abramson Cancer Center at the University of Pennsylvania.
The legacy of Eric Lefkofsky is Groupon. This is a $2.2 billion e-commerce company which is involved in connecting customers with merchants.
Tempus has developed an operating system that is designed for cancer. This is a technology platform. It connects anatomic as well as molecular data along with clinical data that is collated from medical systems spread all over the country. This information is compiled in one place. This allows doctors to devise better-informed and personalized treatments for their patients and more information click here.
Hence chemo and radiation combinations may be adjusted for a patient. This will be based on historical results from those patients who have similar medical backgrounds.
More visit: https://twitter.com/lefkofsky